Elanco Animal Health Incorporated (ELAN) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $24.11. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ELAN = $17.10 (-29.1% from the current price, the stock appears overvalued). Analyst consensus target is ELAN = $28 (+15.6% upside).
Valuation: ELAN trades at a trailing Price-to-Earnings (P/E) of -49.7 (S&P 500 average ~25).
Financials: revenue is $4.7B, +2.2%/yr average growth. Net income is $232M (loss), growing at -534.9%/yr. Net profit margin is -4.9% (negative). Gross margin is 43.5% (-13.2 pp trend).
Balance sheet: total debt is $4.0B against $6.5B equity (Debt-to-Equity (D/E) ratio 0.61, moderate). Current ratio is 2.17 (strong liquidity). Debt-to-assets is 30.1%. Total assets: $13.4B.
Analyst outlook: 14 / 20 analysts rate ELAN as buy (70%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 86/100 (Pass), Growth 30/100 (Fail), Past 25/100 (Fail), Health 50/100 (Partial), Moat 58/100 (Partial), Future 79/100 (Pass), Income 10/100 (Fail).
